(secondQuint)Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics.

 Phase 0 / I: At level 1 it includes three patients.

 If any patient suffers dose limiting toxicity (DLT), it proceeds to the increase in dose to the next level.

 If 2/3 patients experience DLT, he will close the increased dose and extended / investigate the previous dose level with 3 additional patients.

 If the level 2, but less than 1/3 the minimum of 6 patients experience TLD is reached, the phase I be suspended because not expected another rise above Level 2.

 Dose levels: - Level 1: Nintedanib 150 mg twice daily + oral letrozole 2.

5 mg / day orally, in a cycle of 28 days.

 - Level 2: Nintedanib 200 mg twice daily via oral + letrozole 2.

5 mg / day orally, in a cycle of 28 days.

 - At least the first cycle will be administered during Phase I.

 A total of six four-week cycles were administered at the discretion of the investigator.

.

 Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics@highlight

Open, multicenter phase I with gradual increase in dosage to evaluate the safety and tolerability of orally administered nintedanib plus letrozole orally (2.

5 mg / day) for patients with breast cancer.

 Nintedanib is administered twice a day orally for 28 consecutive days (Days 1-28) in 4-week cycles.

